MLYS
Mineralys Therapeutics, Inc.NASDAQHealthcare$26.97+4.67%ClosedMarket Cap: $1.79B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.52
P/S
0.00
EV/EBITDA
-10.21
DCF Value
$2.53
FCF Yield
-7.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.9%
ROA
-23.4%
ROIC
-26.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-38.3M | $-32.2M | $-0.40 | — |
| FY 2025 | $0.00 | -Infinity% | $-170.6M | $-154.7M | $-2.29 | — |
| Q3 2025 | $0.00 | -Infinity% | $-41.1M | $-36.9M | $-0.52 | — |
| Q2 2025 | $0.00 | NaN% | $-46.7M | $-43.3M | $-0.66 | — |
| Q1 2025 | $0.00 | NaN% | $-44.4M | $-42.2M | $-0.79 | — |
| Q4 2024 | $0.00 | NaN% | $-51.8M | $-48.9M | $-0.98 | — |
| FY 2024 | $0.00 | NaN% | $-192.4M | $-177.8M | $-3.66 | — |
| Q3 2024 | $0.00 | NaN% | $-60.1M | $-56.3M | $-1.13 | — |
| Q2 2024 | $0.00 | NaN% | $-45.2M | $-41.0M | $-0.83 | — |
| Q1 2024 | $0.00 | -Infinity% | $-35.4M | $-31.5M | $-0.70 | — |
| Q4 2023 | $0.00 | NaN% | $-27.7M | $-24.4M | $-0.61 | — |
| FY 2023 | $0.00 | NaN% | $-84.7M | $-71.9M | $-1.99 | — |